Access cutting-edge cipn - chemotherapy-induced peripheral neuropathy treatment through this phase 2 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Philadelphia location
Preparing your pre-screening questions…
Access cipn - chemotherapy-induced peripheral neuropathy specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cipn - chemotherapy-induced peripheral neuropathy treatment provided free
Check if you qualify for this cipn - chemotherapy-induced peripheral neuropathy clinical trial in Philadelphia, PA
No-Cost Study Care
Local to Philadelphia
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The investigators hypothesize that Scrambler therapy with duloxetine, compared to duloxetine-based usual care, will result in greater improvement in CIPN as measured by the BPI-Short Form. In addition, the investigators will further assess pain using the EORTC CIPN-20 and determine whether Scrambler therapy results in improved levels of function as measured with the PDQ, and a decreased need for opioid medications. Our primary objective is to investigate whether Scrambler therapy with duloxetine is superior to duloxetine-based usual care in achieving at least a 50% reduction in pain scores, when comparing the cross-sectionally measured "average" pain score at day 35 to the cross-sectionally measured "average" pain score at baseline.
Sponsor: Fox Chase Cancer Center
Yes, this clinical trial (NCT06914557) has an active research site in Philadelphia, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for cipn - chemotherapy-induced peripheral neuropathy treatment options in Philadelphia, PA, this clinical trial (NCT06914557) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced cipn - chemotherapy-induced peripheral neuropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all cipn - chemotherapy-induced peripheral neuropathy clinical trials near you to find additional studies recruiting in your area.
See all pulmonary embolism clinical trials recruiting in Philadelphia — not just this study.
Browse Pulmonary Embolism Trials in Philadelphia →